

II. AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace all prior versions, and listings, of the claims in the application.

Listing of Claims:

1-37. (cancelled)

38. (currently amended) A method of effectively treating pain in humans or other mammals, comprising orally administering to a human patient a an oral dosage form comprising an analgesic compounds combination consisting essentially of (i) nabumetone and/or at least one pharmaceutically acceptable salt thereof; and (ii) oxycodone and/or at least one pharmaceutically acceptable salt thereof.

39-46. (cancelled)

47. (previously presented) The method of claim 38, wherein the ratio of oxycodone and/or at least one pharmaceutically acceptable salt thereof to nabumetone and/or at least one pharmaceutically acceptable salt thereof is from about 0.0001:1 to about 1:1.

48. (previously presented) The method of claim 38, wherein the oxycodone is present in the pharmaceutically acceptable salt form.

49. (previously presented) The method of claim 38, wherein the dosage form further comprises a sustained release carrier which provides a sustained release of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

50. (previously presented) The method of claim 38, wherein the dosage form further comprises a sustained release carrier which provides a sustained release of the nabumetone and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof.

51. (new): The method of claim 38, wherein the nabumetone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 0.5 mg to about 1500 mg.

52. (new) The method of any of claims 38, 47, 49, 50 or 51, wherein the analgesic compounds comprise oxycodone in an amount from 2.5 mg to 800 mg.